Zhejiang Haisen Pharmaceutical Co., Ltd. Class A
SSZSE:00136719.66
CNY
+0.64
(+3.36%)
ISIN
CNE1000061L9
Return %
Stock
S&P 500
1Y
-18.79
13.14
3Y
8.47
80.78
5Y
- -
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Lin Ai
- Full Time Employees
- 705
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- Dongyang China
- IPO Date
- Apr 10, 2023
- Website
- dongyang.pharm.com
- Similar Companies
- Business
- Zhejiang Haisen Pharmaceutical Co., Ltd. is a China-based pharmaceutical manufacturing company primarily engaged in the research, development, production, and commercialization of active pharmaceutical ingredients (APIs), advanced pharmaceutical intermediates, and finished pharmaceutical preparations. Founded in 1998 and headquartered in Dongyang, Zhejiang Province, China, the company operates across the specialty chemicals, human health, and generic pharmaceutical sectors. The company's product portfolio comprises: antipyretic, analgesic, and non-steroidal anti-inflammatory APIs and intermediates, including metamizole sodium (analgin), paracetamol (acetaminophen), dexketoprofen trometamol, and L-lysine acetylsalicylate; cardiovascular system APIs and intermediates, featuring diltiazem hydrochloride and benazepril hydrochloride; digestive system and mucosal protective agents, including sucralfate and glutamine; central nervous system and autonomic agents, such as neostigmine methylsulfate; and finished chemical dosage forms, encompassing diltiazem hydrochloride tablets, metamizole sodium tablets, and sucralfate suspensions. Zhejiang Haisen Pharmaceutical serves pharmaceutical formulation manufacturers, clinical healthcare providers, and chemical distributors across domestic Chinese markets as well as international destinations across Europe, North America, South America, and Asia, holding regulatory accreditations including China NMPA, European EDQM CEP, and U.S. FDA compliance. In recent developments, the company completed its initial public offering and listed its Class A shares on the Main Board of the Shenzhen Stock Exchange (Ticker: SZSE:001367), deploying the raised proceeds toward large-scale manufacturing capacity expansion, automated workshop upgrades, and the construction of an advanced research and development center. Furthermore, the company has recently broadened its international market reach through accelerated foreign regulatory drug master file (DMF) registrations, initiated commercial scale-up for newly developed API lines, and established long-term strategic supply partnerships with prominent domestic and multinational generic pharmaceutical enterprises.